Remicade Biosimilars Market By Disease Indication (Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis, and Others), and By Region - Trends, Analysis and Forecast till 2034

Report Code: PMI485822 | Publish Date: April 2024 | No. of Pages: 180

Global Remicade Biosimilars Market Companies

  • Janssen Biotech, Inc.
  • Merck and Company, Inc.
  • Alvogen
  • Pfizer, Inc.
  • Celltrion
  • Nippon Kayaku
  • Napp Pharmaceuticals.

Recent News:

  • In August 2020, South Korea's Celltrion and the United Kingdom's Intract Pharma joined forces to co-develop infliximab, a biosimilar of Johnson & Johnson's immunology blockbuster Remicade, and create the first tablet version of the drug worldwide. With the medication already available in intravenous and subcutaneous forms, Celltrion anticipates that this partnership will strengthen its market share in the Crohn's disease and ulcerative colitis domains.
  • The FDA authorized Avsola (infliximab-axxq), the fourth Remicade biosimilar, in December 2019. This tumor necrosis factor blocker is prescribed to patients with psoriatic arthritis, plaque psoriasis, ankylosing spondylitis, ulcerative colitis, rheumatoid arthritis, and Crohn's disease when used in conjunction with methotrexate.